Header Logo

Connection

Warren Jackman to Anti-Arrhythmia Agents

This is a "connection" page, showing publications Warren Jackman has written about Anti-Arrhythmia Agents.
Connection Strength

0.515
  1. Pharmacological prevention and termination of focal atrial fibrillation. Europace. 2012 Mar; 14(3):426-30.
    View in: PubMed
    Score: 0.093
  2. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15; 123(10):e269-367.
    View in: PubMed
    Score: 0.090
  3. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Am J Cardiol. 1988 Dec 20; 62(19):8L-19L.
    View in: PubMed
    Score: 0.077
  4. Direct endocardial recording from an accessory atrioventricular pathway: localization of the site of block, effect of antiarrhythmic drugs, and attempt at nonsurgical ablation. Circulation. 1983 Nov; 68(5):906-16.
    View in: PubMed
    Score: 0.054
  5. Electrophysiology of oral encainide. Am J Cardiol. 1982 Apr 01; 49(5):1270-8.
    View in: PubMed
    Score: 0.048
  6. Non-pharmacological, non-ablative approaches for the treatment of atrial fibrillation: experimental evidence and potential clinical implications. J Cardiovasc Transl Res. 2011 Feb; 4(1):35-41.
    View in: PubMed
    Score: 0.022
  7. An acute experimental model demonstrating 2 different forms of sustained atrial tachyarrhythmias. Circ Arrhythm Electrophysiol. 2009 Aug; 2(4):384-92.
    View in: PubMed
    Score: 0.020
  8. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia. Am J Cardiol. 1988 Dec 20; 62(19):31L-36L.
    View in: PubMed
    Score: 0.019
  9. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988 Sep-Oct; 31(2):115-72.
    View in: PubMed
    Score: 0.019
  10. Antifibrillatory actions of cisatracurium: an atrial specific M2 receptor antagonist. J Cardiovasc Electrophysiol. 2008 Aug; 19(8):861-8.
    View in: PubMed
    Score: 0.018
  11. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007 Jun; 4(6):816-61.
    View in: PubMed
    Score: 0.017
  12. Ventricular tachyarrhythmias in the long QT syndromes. Med Clin North Am. 1984 Sep; 68(5):1079-109.
    View in: PubMed
    Score: 0.014
  13. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms. Am Heart J. 1982 Feb; 103(2):177-84.
    View in: PubMed
    Score: 0.012
  14. The monophasic action potential in clinical cardiology. Clin Cardiol. 1991 Jun; 14(6):505-10.
    View in: PubMed
    Score: 0.006
  15. Role of electrophysiologic testing in managing patients who have ventricular tachycardia unrelated to coronary artery disease. Am J Cardiol. 1982 Jul; 50(1):165-71.
    View in: PubMed
    Score: 0.003
  16. Clinical transvenous cardioversion of recurrent life-threatening ventricular tachyarrhythmias: low energy synchronized cardioversion of ventricular tachycardia and termination of ventricular fibrillation in patients using a catheter electrode. Am Heart J. 1982 May; 103(5):789-94.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.